Bio-Rad launches SARS-CoV-2 S Gene Alpha, Beta, Gamma and Epsilon variant controls for research testing
Bio-Rad Laboratories has launched the SARS-CoV-2 S Gene Alpha, Beta, Gamma and Epsilon Variant Controls as part of the company’s Exact Diagnostics line of molecular quality control products for research testing.
The Exact Diagnostics SARS-CoV-2 S Gene Variant Controls are intended to be validated as independent external run controls and used for research testing with molecular assays targeting mutations in the Spike (S) gene. The products are to be used with assays detecting SARS-CoV-2 variant RNA and to be processed in the same manner as patient specimens to monitor all the steps of molecular assays.
This line of variant controls consists of synthetic RNA transcripts of the respective variant SARS-CoV-2 S genes in a matrix simulating transport media. Because the products also contain human genomic DNA (human gDNA; which includes the human RNase P) for internal control needs, they also enable laboratories to monitor the entire process of a molecular assay, including extraction (optional), amplification, and detection.
